Perrigo (PRGO) Income from Continuing Operations (2012 - 2026)

Perrigo's (PRGO) quarterly Income from Continuing Operations came in at 389800000.0 in Q1 2026, down 389900.0% year-on-year from N/an in Q1 2025, and up 72.44% on a QoQ basis from 1414600000.0 in Q4 2025.

Perrigo (PRGO) Income from Continuing Operations (2012 - 2026) Analysis & Trends

Perrigo (PRGO) has 15 years of Income from Continuing Operations data on file, last reported at 389800000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 389900.0% year-over-year to 389800000.0 in Q1 2026; TTM through Mar 2026 was 1792200000.0, a 988.16% decrease from a year earlier, with the FY2025 full-year figure at 1402300000.0, down 772.62% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 389800000.0, up from 1414600000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PRGO reached as high as 15400000.0 in Q3 2023 and fell as low as 1414600000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 122841176.47 across 5 years, with a median of 12700000.0 in 2022.
  • Across the five-year window, Income from Continuing Operations soared 472.73% in 2024 and sank 389900.0% in 2026, its largest moves.
  • Year by year, Income from Continuing Operations stood at 12700000.0 in 2022, then plunged by 118.11% to 27700000.0 in 2023, then plunged by 49.82% to 41500000.0 in 2024, then sank by 3308.67% to 1414600000.0 in 2025, then surged by 72.44% to 389800000.0 in 2026.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were 389800000.0 in Q1 2026, 1414600000.0 in Q4 2025, and 12700000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Perrigo 1.40 Bn 1.05 Bn 325.50 Mn -389.80 Mn

Historic Data

Download Data
DateValue
Mar 28, 2026 -389.80 Mn
Dec 31, 2025 -1.41 Bn
Sep 27, 2025 12.70 Mn
Jun 28, 2025 -500,000.00
Mar 29, 2025 100,000.00
Dec 31, 2024 -41.50 Mn
Sep 28, 2024 -17.60 Mn
Jun 29, 2024 -105.70 Mn
Mar 30, 2024 4.10 Mn
Dec 31, 2023 -27.70 Mn
Sep 30, 2023 15.40 Mn
Jul 1, 2023 8.90 Mn
Apr 1, 2023 -1.10 Mn
Dec 31, 2022 -12.70 Mn
Oct 1, 2022 -52.10 Mn
Jul 2, 2022 -64.90 Mn
Apr 2, 2022 -1.30 Mn
Dec 31, 2021 32.10 Mn
Oct 2, 2021 -53.90 Mn
Jul 3, 2021 -111.90 Mn